VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit

Core Viewpoint - A class action lawsuit has been filed against Vistagen Therapeutics, Inc. on behalf of purchasers of its common stock between April 1, 2024, and December 16, 2025, due to misleading statements regarding the company's drug fasedienol and its clinical trials [1][5][6]. Group 1: Lawsuit Details - The lawsuit claims that Vistagen provided investors with overly positive information about the development and commercialization of fasedienol, an investigational drug for social anxiety disorder, while concealing material adverse facts about its Phase 3 PALISADE-3 trial [5][6]. - Investors are eligible for compensation without any out-of-pocket fees through a contingency fee arrangement if they purchased Vistagen common stock during the class period [2][3]. Group 2: Legal Representation - The Rosen Law Firm, which has a strong track record in securities class actions, is representing the investors and encourages them to select qualified counsel [4]. - Investors wishing to join the class action can do so by visiting the provided link or contacting the firm directly [3][7].